Our Latest News - BUHLMANN

BUHLMANN News

Faecal Calprotectin Predicts Endoscopic and Histological Activity

BÜHLMANN fCAL® ELISA Citation Lara Hart et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis, Journal of Crohn's and Colitis, Volume 14, Issue 1, January 2020, DOI: doi.org/10.1093/ecco-jcc/jjz107 READ CITATION BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use. Health Canada License: 80726 This citation describes applications that are outside of
Continue Reading

Quantum Blue® Anti-Adalimumab: Development and evaluation of a rapid test

BÜHLMANN Quantum Blue® Anti-Adalimumab Citation: B Ricken, M Schneider, F Bantleon, S Velayutham, D Trapani, J Afonso, F Magro, A Abel. Quantum Blue® Anti-Adalimumab: Development and evaluation of a point of care rapid test for measuring anti-adalimumab antibodies in human serum. ECCO 2019 P153. DOI: doi.org/10.1093/ecco-jcc/jjy222.277 BÜHLMANN Quantum Blue® Anti-Adalimumab is for Research Use Only in
Continue Reading

Quantum Blue®Anti-Infliximab and Anti-Adalimumab Tests Now Available

New Quantum Blue® TDM Assays BÜHLMANN is proud to introduce Quantum Blue® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid test portfolio.  These new assays together with the infliximab and adalimumab trough level rapid tests offer the complete package for infliximab and adalimumab TDM testing on the popular Quantum Blue® platform. BÜHLMANN Quantum Blue®
Continue Reading

ECCO 2020 Poster – IBDoc Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)

IBDoc® Citation: Avery, P. et. al. N05: IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH).  ECCO 2020, Feb 12-15. Highlights from this Publication “ …This data also helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments....” Read Citation Health
Continue Reading

ECCO 2020 Poster: IBD Home at GHP Stockholm Gastro Center in Sweden

IBDoc® Citation: S. Jäghult et. al.  N08: IBD Home at GHP Stockholm Gastro Center in Sweden. ECCO 2020, Feb 12-15. Highlights from this Publication “ …The majority (n = 24) stated that it was easy to install IBD Home. A total of nine patients noted that their participation in their own health care had increased...” “
Continue Reading

ECCO 2020 Poster – An evaluation of the impact of IBDoc

BÜHLMANN IBDoc®: Sugrue, K. et al.  N12: An evaluation of the impact of IBDoc in clinical practice 5 years after introduction.  ECCO 2020, Feb 12 – 15, 2020. Vienna, Austria. Highlights from this Publication “This study shows the benefits of using IBDoc® in clinical practice. It is central to facilitating a fast track system for patients
Continue Reading

Labsense News Fall 2019 Edition


Continue Reading

Flow CAST- Assay Overview Video

Flow CAST®: Research Use Only in the US. Not for diagnostic procedures. Health Canada License:101781 BÜHLMANN Flow CAST® and Basophil Activation (BAT): Basophil Activation Tests (BAT) have been extensively studied as in vitro functional assays and have demonstrated superior accuracy as compared to other blood tests for various allergies (1).  BÜHLMANN  provides a broad range of
Continue Reading

Quantum blue anti-infliximab: development and evaluation of a rapid test

BÜHLMANN Quantum Blue® Anti-Infliximab Citation: F. I. Bantleona, M. Schneidera, B. Rickena, S. Velayuthama, D. Trapania, J. Afonsob, F. Magrob, A. P. Abel. Quantum Blue® Anti-Infliximab: Development and evaluation of a point of care rapid test for measuring anti-infliximab antibodies in human serum. ECCO 2019 P202. DOI: 10.1093/ecco-jcc/jjy222.326.  Highlight from this Publication “...Quantum Blue® Anti-Infliximab test
Continue Reading

Visit BUHLMANN at CDDW 2020

Canadian Digestive Diseases Week (CDDW) 2020 BUHLMANN Diagnostics Corp Booth: #13 Feb 28 - Mar 1, 2020 | Fairmont Queen Elizabeth | Montreal, Quebec Learn More Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the first in-vitro diagnostic POC and home testing device to measure the inflammatory marker,
Continue Reading